Ubiquitin-specific protease 6 (USP6) (USP6)

Ubiquitin-specific protease 6 (USP6), also known as TRE17, is a deubiquitinating enzyme (DUB) that plays a pivotal role in the pathogenesis of various mesenchymal and epithelial tumors (UniProt, GeneCards). It is a hominoid-specific protein that regulates the stability and localization of key signaling molecules by removing ubiquitin chains, thereby preventing their proteasomal degradation (Wikipedia). USP6 is most notably associated with chromosomal translocations in benign but locally aggressive lesions, such as aneurysmal bone cysts and nodular fasciitis, where its overexpression is driven by promoter-swapping fusions (NIH). These fusions lead to the constitutive activation of downstream pathways, including NF-kappa-B, JAK-STAT, and Wnt/beta-catenin, which promote cell proliferation, invasion, and inflammation (ResearchGate). In addition to its oncogenic role, USP6 has been found to act as a tumor suppressor in certain contexts, such as Ewing sarcoma, by enhancing anti-tumor immune responses (NIH). Therapeutic targeting of USP6 primarily involves the development of small molecule inhibitors aimed at its catalytic cysteine-type deubiquitinase domain to restore normal protein turnover and suppress oncogenic signaling (ResearchGate).

Other names

TRE17Tre-2HRP1TRESMCRUbiquitin carboxyl-terminal hydrolase 6Proto-oncogene TRE-2Ubiquitin-specific-processing protease 6Deubiquitinating enzyme 6

Inhibition of deubiquitinase activity, leading to the degradation of stabilized oncogenic substrates and suppression of downstream signaling pathways such as NF-kappa-B, JAK-STAT, and Wnt/beta-catenin.